Wound Care Biologics - Global Strategic Business Report

Global Wound Care Biologics Market to Reach $5 Billion by 2030

The global market for Wound Care Biologics estimated at US$1.7 Billion in the year 2022, is projected to reach a revised size of US$5 Billion by 2030, growing at a CAGR of 14.1% over the analysis period 2022-2030. Biologic Skin Substitutes, one of the segments analyzed in the report, is projected to record 14.8% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Topical Agents segment is readjusted to a revised 12.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $473.1 Million, While China is Forecast to Grow at 20.4% CAGR

The Wound Care Biologics market in the U.S. is estimated at US$473.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 12.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Select Competitors (Total 42 Featured) -

• Acell
• Anika Therapeutics
• Integra Lifesciences
• Kerecis
• Marine Polymer Technologies
• Mimedx Group
• Mölnlycke Health Care AB (Investor AB)
• Organogenesis
• Osiris Therapeutics
• Smith & Nephew

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year